Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Pancragen

Lys-Glu-Asp-Trp, KEDW

Quick Stats
Studies 7
Trials 18
Score 3
2014 pubmed

[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys].

Goncharova. N D ND; Ivanova. L G LG; Oganian. T É TÉ; Vengerin. A A AA; Khavinson. V Kh VKh

Key Findings

  • Old monkeys showed slower glucose disappearance and higher insulin/C‑peptide peaks compared with young monkeys.
  • Pancragen (50 µg per animal daily for 10 days, IM) markedly increased glucose clearance and normalized insulin and C‑peptide responses in old monkeys.
  • The improved pancreatic function partially persisted for about three weeks after the peptide was stopped.

Practical Outcomes

  • Pancragen looks promising as a potential anti‑aging tool to improve glucose handling and pancreatic hormone balance, but the evidence is limited to non‑human primates. Biohackers should treat this as a hypothesis‑generating finding; human dosing, safety, and long‑term effects are unknown, so any self‑experiment would be highly experimental and risky.

Summary

In older female rhesus monkeys, a short 10‑day course of the tiny peptide pancragen (Lys‑Glu‑Asp‑Trp) given by injection helped the pancreas work better: the monkeys cleared sugar from the blood faster and had more normal insulin and C‑peptide spikes after a glucose drink. Some of the benefit stuck around for a few weeks after stopping the peptide.

Abstract

Significant increase of the elderly in the demographic structure of a modern society is one of the main reasons for increase in the number of patients with diabetes type 2 and impaired glucose tolerance. The purpose of this research was to study impact of Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas of non-human primates, female rhesus monkeys, and to elucidate the possibil- ity of its use for correction age-related dysfunction of pancreatic islet apparatus. In old animals after the glucose administration (standard dose) in control period, a reduced glucose "disappearance" rate and a higher values of insulin and C-peptide peaks (5 and 15 min after the glucose injection) were observed in comparison with young animals in similar experiments. Pancragen administration (50 μg/animal per day during 10 days, intramuscularly) to old monkeys caused markedly increased the glucose "disappear- ance" rate, normalized the plasma insulin and C-peptide dynamics in response to glucose administration. The recovering effect of Pancragen on the function of the pancreas partially remained 3 weeks after discontinuation of the drug. Thus, Pancragen is a promising factor for restoring the age-related endocrine dysfunction of primates.

Study Information

Provider

pubmed

Year

2014